Dr. Mah brings more than 30 years of senior leadership experience in the pharmaceutical and biotech industries across public and privately held companies. His extensive background spans corporate governance, late-stage clinical development, regulatory strategy and global biotech leadership across several successful ventures.

“We are honored to welcome Dr. Mah to Akceso Advisors AG’s Board,” said Dr. Andras Incze CEO, Founder, and Chairman of the Board. “His exceptional track record in strategic decision-making and executive leadership in successful biotech ventures will provide invaluable guidance as we further expand our global reach and continue to support our clients navigating today’s increasingly unpredictable business environment, addressing the complex market access challenges that increasingly impact pharmaceutical development.”

Dr. Mah is Chairman of BioVersys AG (SIX-listed), and sits on the boards of OSR Holdings Inc. (NASDAQ-listed) and Vaccentis AG. He was previously Chief Executive Officer of the Canyon Pharmaceuticals Group AG, where he successfully transacted a corporate inversion of a U.S.-registered company to Switzerland.

Earlier in his career, Dr. Mah held a series of senior leadership roles at Novartis and Ciba, including Global Head of Clinical Safety and Epidemiology, Head of Drug Regulatory Affairs Europe, and Head of the Development Integration Office during the integration of Chiron into Novartis. He was a member of the Novartis Corporate Executive Group and the Board of Directors of Novartis Europharm Ltd. in the UK.

Dr. Mah is an award-winning biotech leader, having received the Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants for leading Canyon Pharmaceuticals in the development and launch of Iprivask (desirudin for injection). He subsequently oversaw the successful asset transaction of the product.

“I am delighted to join the Board of Akceso Advisors,” said Dr. Seng Chin Mah. “The company has built an exceptional reputation for professional rigor, strategic insight and sophisticated cloud-based tools, and is committed to improving patient access to innovative therapies. I look forward to contributing to its continued growth and mission.”